Ryu 2015.

Study characteristics
Methods	Study design: randomized controlled trial Study dates: March 2012 to March 2013 Setting: outpatient, single center, national Country: Korea
Participants	Inclusion criteria: Men between 50 and 80 years old IPSS > 10 points Qmax 5 to 15 mL/s for a voided volume of at least 150 mL Postvoiding volume < 150 mL Prostate volume > 25 cm3 PSA < 4 ng/mL Exclusion criteria: History of bladder diseases such as: micturition; urethral stenosis; prostate cancer; pelvic radiotherapy; repeated infection of urinary tract. chronic bacterial prostatitis. Patients with clinically significant cardiovascular disease Hematuria Insulin‐dependent diabetes mellitus History of severe hepatic failure or abnormal liver function test Known hypersensitivity to 1 of the study drugs Medical history of BPH during the past 12 months Sample size: 120 randomized participants Age (years): Group 1 mean (SD): 62.5 (1.21) Group 2 mean (SD): 63.4 (1.44) IPSS score (baseline): Group 1 mean (SD): 19.6 (0.73) Group 2 mean (SD): 20 (0.85) Prostate size: Group 1 mean (SD): 30.1 (0.93) Group 2 mean (SD): 30.2 (0.67)
Interventions	Group 1 (n = 60): Serenoa repens (Permixon) 320 mg/day for 12 months Group 2 (n = 60): only the co‐intervention Co‐interventions: tamsulosin 0.2 mg/day
Outcomes	Urinary symptoms How measured: IPSS score Time points measured: 0, 6, and 12 months Time points reported: 0, 6, and 12 months Subgroups: none Quality of life How measured: LUTS‐related quality of life scores Time points measured: 0, 6, and 12 months Time points reported: 0, 6, and 12 months Subgroups: none Adverse events How measured: not described Time points measured: 0, 6, and 12 months Time points reported: 12 months Subgroups: none Other outcomes measured in the trial: PSA and prostate volume, Qmax
Notes	Funding sources: not available Declarations of interest: not available